BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4312 related articles for article (PubMed ID: 17395339)

  • 1. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
    Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis.
    Holzmuller P; Cavaleyra M; Moreaux J; Kovacic R; Vincendeau P; Papierok G; Lemesre JL
    Vet Immunol Immunopathol; 2005 Jul; 106(3-4):247-57. PubMed ID: 15963823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
    Gradoni L; Foglia Manzillo V; Pagano A; Piantedosi D; De Luna R; Gramiccia M; Scalone A; Di Muccio T; Oliva G
    Vaccine; 2005 Nov; 23(45):5245-51. PubMed ID: 16054272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective humoral and cellular immunoprotective responses in Li ESAp-MDP vaccinated protected dogs.
    Bourdoiseau G; Hugnet C; Gonçalves RB; Vézilier F; Petit-Didier E; Papierok G; Lemesre JL
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):71-8. PubMed ID: 19046774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
    Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
    Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.
    de Lima VM; Ikeda FA; Rossi CN; Feitosa MM; Vasconcelos RO; Nunes CM; Goto H
    Vet Immunol Immunopathol; 2010 Jun; 135(3-4):296-302. PubMed ID: 20132994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
    Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
    Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
    Saldarriaga OA; Travi BL; Park W; Perez LE; Melby PC
    Vaccine; 2006 Mar; 24(11):1928-40. PubMed ID: 16310897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
    Rafati S; Nakhaee A; Taheri T; Taslimi Y; Darabi H; Eravani D; Sanos S; Kaye P; Taghikhani M; Jamshidi S; Rad MA
    Vaccine; 2005 May; 23(28):3716-25. PubMed ID: 15882533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
    Strauss-Ayali D; Baneth G; Shor S; Okano F; Jaffe CL
    Int J Parasitol; 2005 Jan; 35(1):63-73. PubMed ID: 15619517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interpretation of laboratory data during cryptic leishmaniasis in dog].
    Gravino AE
    Parassitologia; 2004 Jun; 46(1-2):227-9. PubMed ID: 15305723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological evaluation of experimentally infected dogs by LicTXNPx-ELISA and amastigote-flow cytometry.
    Silvestre R; Santarém N; Cunha J; Cardoso L; Nieto J; Carrillo E; Moreno J; Cordeiro-da-Silva A
    Vet Parasitol; 2008 Nov; 158(1-2):23-30. PubMed ID: 18848397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood mononuclear cell supernatants from asymptomatic dogs immunized and experimentally challenged with Leishmania chagasi can stimulate canine macrophages to reduce infection in vitro.
    Rodrigues CA; Batista LF; Teixeira MC; Pereira AM; Santos PO; de Sá Oliveira GG; de Freitas LA; Veras PS
    Vet Parasitol; 2007 Feb; 143(3-4):197-205. PubMed ID: 17045743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT; Vale AM; França da Silva JC; da Costa RT; Quetz Jda S; Martins Filho OA; Reis AB; Corrêa Oliveira R; Machado-Coelho GL; Bueno LL; Bethony JM; Frank G; Nascimento E; Genaro O; Mayrink W; Reed S; Campos-Neto A
    Vet Res; 2005; 36(5-6):827-38. PubMed ID: 16120256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs.
    de Andrade RA; Reis AB; Gontijo CM; Braga LB; Rocha RD; Araújo MS; Vianna LR; Martins-Filho OA
    Vet Immunol Immunopathol; 2007 Mar; 116(1-2):85-97. PubMed ID: 17287029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
    Saraiva EM; de Figueiredo Barbosa A; Santos FN; Borja-Cabrera GP; Nico D; Souza LO; de Oliveira Mendes-Aguiar C; de Souza EP; Fampa P; Parra LE; Menz I; Dias JG; de Oliveira SM; Palatnik-de-Sousa CB
    Vaccine; 2006 Mar; 24(13):2423-31. PubMed ID: 16386824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 216.